康辰药业
(603590)
| 流通市值：47.99亿 | | | 总市值：48.23亿 |
| 流通股本：1.58亿 | | | 总股本：1.59亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 462,795,750.69 | 214,870,397.3 | 915,123,690.39 | 692,220,405.14 |
| 营业收入 | 462,795,750.69 | 214,870,397.3 | 915,123,690.39 | 692,220,405.14 |
| 二、营业总成本 | 354,733,995.85 | 156,475,838.57 | 724,859,248.04 | 534,795,468.49 |
| 营业成本 | 47,164,104.37 | 21,901,152.37 | 92,250,913.37 | 68,161,056.22 |
| 税金及附加 | 5,857,136.93 | 2,850,290.87 | 10,791,519.64 | 7,751,201.78 |
| 销售费用 | 189,768,537.55 | 81,475,739.02 | 428,820,252.58 | 326,641,391.08 |
| 管理费用 | 67,920,853.58 | 35,045,880.52 | 138,695,728.15 | 99,101,178.46 |
| 研发费用 | 40,002,569.39 | 13,342,212.47 | 51,860,806.17 | 32,800,011.37 |
| 财务费用 | 4,020,794.03 | 1,860,563.32 | 2,440,028.13 | 340,629.58 |
| 其中:利息费用 | 4,594,099 | 2,200,994.33 | 7,533,347.13 | 5,404,523.56 |
| 其中:利息收入 | 2,016,100.87 | 976,580.38 | 8,986,369.54 | 7,449,849.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,627,457.82 | 123,342.99 | 4,176,636.3 | 804,230.25 |
| 加:投资收益 | 11,965,245.63 | 2,539,854.82 | 17,697,524 | 9,270,027.04 |
| 资产处置收益 | - | - | -454,286.75 | 130,668.15 |
| 信用减值损失(新) | -596,307.96 | -2,142,575.49 | -14,548,175.39 | -10,611,214.32 |
| 其他收益 | 3,980,181.2 | 1,637,249.25 | 5,880,499.89 | 4,243,921.46 |
| 四、营业利润 | 126,038,331.53 | 60,552,430.3 | 203,016,640.4 | 161,262,569.23 |
| 加:营业外收入 | 62,686.03 | 1.8 | 339,472.65 | 20,306.74 |
| 减:营业外支出 | 5,162,216 | 1,850,101.75 | 13,669,682.24 | 13,071,584.05 |
| 五、利润总额 | 120,938,801.56 | 58,702,330.35 | 189,686,430.81 | 148,211,291.92 |
| 减:所得税费用 | 20,374,072.16 | 10,190,267.26 | 20,263,005.94 | 13,908,706.93 |
| 六、净利润 | 100,564,729.4 | 48,512,063.09 | 169,423,424.87 | 134,302,584.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 100,564,729.4 | 48,512,063.09 | 169,423,424.87 | 134,302,584.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 95,722,610.48 | 47,213,574.31 | 165,966,936.53 | 127,880,071.73 |
| 少数股东损益 | 4,842,118.92 | 1,298,488.78 | 3,456,488.34 | 6,422,513.26 |
| 扣除非经常损益后的净利润 | 92,183,828.23 | 46,066,635.67 | 161,758,518.8 | 133,026,315.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.61 | 0.3 | 1.05 | 0.81 |
| (二)稀释每股收益 | 0.61 | 0.3 | 1.04 | 0.81 |
| 八、其他综合收益 | -23,579,061.36 | 4,785,418.36 | -10,653,418.31 | -48,898,274.85 |
| 归属于母公司股东的其他综合收益 | -23,579,061.36 | 4,785,418.36 | -10,653,418.31 | -48,898,274.85 |
| 九、综合收益总额 | 76,985,668.04 | 53,297,481.45 | 158,770,006.56 | 85,404,310.14 |
| 归属于母公司股东的综合收益总额 | 72,143,549.12 | 51,998,992.67 | 155,313,518.22 | 78,981,796.88 |
| 归属于少数股东的综合收益总额 | 4,842,118.92 | 1,298,488.78 | 3,456,488.34 | 6,422,513.26 |
| 公告日期 | 2026-08-26 | 2026-04-23 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |